Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Similar risk reduction but fewer side effects would predict more uptake and compliance with low (5 mg) versus full (20 mg) dose tamoxifen. Benefit with low dose is demonstrated for perimenopausal/postmenopausal women with intraepithelial neoplasia and high lesion Ki-67. Longer follow-up needed to determine benefit with low lesion Ki-67.See related article by DeCensi et al., p. 3576.

Keyphrases

low dose
high grade
breast cancer cells
estrogen receptor
positive breast cancer
neoadjuvant chemotherapy
postmenopausal women
bone mineral density
high dose
squamous cell carcinoma
body composition